NCT05425134 is a clinical trial of PET/CT-based Deep Learning Signature in Non-small Cell Lung Cancer, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT05425134?

NCT05425134 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT05425134?

Interventions in NCT05425134: PET/CT-based Deep Learning Signature.

What condition does NCT05425134 study?

NCT05425134 studies Non-small Cell Lung Cancer.

Is NCT05425134 still recruiting?

NCT05425134 is currently status unknown. Last updated 9 February 2023.

Last reviewed 2023-02-09 · How we verify

NCT05425134

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer

Status unknown Last updated 9 February 2023

What this trial tests

trial testing PET/CT-based Deep Learning Signature in Non-small Cell Lung Cancer in 5,000 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	1 January 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	4 locations across China

Drugs / interventions tested

PET/CT-based Deep Learning Signature

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 20 to 75, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the performance of a PET/CT-based deep learning signature for predicting occult nodal metastasis of clinical stage N0 non-small cell lung cancer in a multicenter prospective cohort.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer.
Zhong Y, Cai C, Chen T, Gui H, et al · · 2023 · cited 39× · PMID 37980411 · DOI 10.1038/s41467-023-42811-4
Targeted Lung Premetastasis Niche: Mechanisms, Strategies, and Application.
Cao C, Lu D, Li H, Pan S, et al · · 2025 · cited 2× · PMID 40470380 · DOI 10.1002/mco2.70248

Verify or expand the search:

Other trials of PET/CT-based Deep Learning Signature

Trials testing the same drug.

NCT05925738 — Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer · unknown

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05425134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 9 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05425134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing